GSS — Genetic Signatures Share Price
0.000.00%
Last trade - 00:00- AU$128.67m
- AU$110.56m
- AU$22.06m
- 31
- 26
- 82
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.18 | ||
| Price to Tang. Book | 3.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.41% | ||
| Return on Equity | -40.28% | ||
| Operating Margin | -109.37% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 7.18 | 14.17 | 28.72 | 35.64 | 22.05 | 9.91 | 33.11 | 33.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +74.62 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company’s principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit and others.
Directors
- Nickolaos Samaras NEC
- John Robert Melki CEO
- Peter Manley CFO
- Douglas S Millar CSO
- Susan Keese GMG
- Michael Aicher EDR
- Neil Gunn DRC
- Anthony Radford DRC
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 15th, 2001
- Public Since
- March 31st, 2015
- No. of Shareholders
- 1,903
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 186,482,642
- Address
- Heart Research Institute, SYDNEY, 2042
- Web
- https://geneticsignatures.com/au/
- Phone
- +61 298707580
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for GSS
Similar to GSS
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Genetic Signatures share price?
As of Today at 19:09 UTC, shares in Genetic Signatures are trading at AU$0.69. This share price information is delayed by 15 minutes.
How has the Genetic Signatures share price performed this year?
Shares in Genetic Signatures last closed at AU$0.69 and the price had moved by -14.29% over the past 365 days. In terms of relative price strength the Genetic Signatures share price has underperformed the ASX All Ordinaries Index by -18.01% over the past year.
What are the analyst and broker recommendations for Genetic Signatures?
The overall consensus recommendation for Genetic Signatures is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Genetic Signatures dividend yield?
Genetic Signatures does not currently pay a dividend.
Does Genetic Signatures pay a dividend?
Genetic Signatures does not currently pay a dividend.
When does Genetic Signatures next pay dividends?
Genetic Signatures does not currently pay a dividend.
How do I buy Genetic Signatures shares?
To buy shares in Genetic Signatures you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genetic Signatures?
As of the previous close price of AU$0.69, shares in Genetic Signatures had a market capitalisation of AU$128.67m.
Where are Genetic Signatures shares listed?
Here are the trading details for Genetic Signatures:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: GSS
What kind of share is Genetic Signatures?
Based on an overall assessment of its quality, value and momentum Genetic Signatures is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genetic Signatures share price forecast for 2024?
The analyst consensus target price for shares in Genetic Signatures is AU$0.75. That is 8.7% above the last closing price of AU$0.69.
Analysts covering Genetic Signatures currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.12 for the next financial year.
What is the trend in the Genetic Signatures share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genetic Signatures. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +24.06%.
As of the last closing price of AU$0.69, shares in Genetic Signatures were trading +29.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genetic Signatures PE Ratio?
The Genetic Signatures PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genetic Signatures?
Genetic Signatures' management team is headed by:
- Nickolaos Samaras - NEC
- John Robert Melki - CEO
- Peter Manley - CFO
- Douglas S Millar - CSO
- Susan Keese - GMG
- Michael Aicher - EDR
- Neil Gunn - DRC
- Anthony Radford - DRC